Diabetic Foot Ulcers - Pipeline Insight, 2022

Diabetic Foot Ulcers - Pipeline Insight, 2022

DelveInsight’s, “Diabetic Foot Ulcerss - Pipeline Insight, 2022,” report provides comprehensive insights about 30+ companies and 34+ pipeline drugs in Diabetic Foot Ulcerss pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Diabetic Foot Ulcerss Understanding

Diabetic Foot Ulcerss: Overview

A Diabetic Foot Ulcerss is an open sore or wound that occurs among the most common complications of patients who have diabetes mellitus which is not well controlled. Diabetic ulcers are the most common foot injuries leading to lower extremity amputation. The most common risk factors for ulcer formation include diabetic neuropathy, structural foot deformity and peripheral arterial occlusive disease. The primary goal in the treatment of foot ulcers is to obtain healing as soon as possible. The management of Diabetic Foot Ulcersss requires offloading the wound, daily saline or similar dressings to provide a moist wound environment, debridement when necessary, antibiotic administration with or without surgical intervention if osteomyelitis or soft tissue infection is present, optimal control of blood glucose, and evaluation and correction of peripheral arterial insufficiency.

""Diabetic Foot Ulcerss - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic Foot Ulcerss pipeline landscape is provided which includes the disease overview and Diabetic Foot Ulcerss treatment guidelines. The assessment part of the report embraces, in depth Diabetic Foot Ulcerss commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Foot Ulcerss collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Foot Ulcerss R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic Foot Ulcerss.

Diabetic Foot Ulcerss Emerging Drugs Chapters

This segment of the Diabetic Foot Ulcerss report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Diabetic Foot Ulcers Emerging Drugs

• AUP 16: Aurealis Therapeutics

AUP-16 is a safe and effective recombinant live biotherapeutic product that features a patented active bacterial vector containing three therapeutic proteins (FGF2, IL4, and CSF1), produced continuously at the site of the wound, providing a combination biologic treatment in one product.

• CSTC 1: Charsire Biotechnology Corporation

CSTC 1 is being developed by Charsire Biotechnology, for the treatment of diabetic foot ulcer.Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Diabetic Foot Ulcers.

Further product details are provided in the report……..

Diabetic Foot Ulcerss: Therapeutic Assessment

This segment of the report provides insights about the different Diabetic Foot Ulcerss drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Diabetic Foot Ulcerss

There are approx. 30+ key companies which are developing the therapies for Diabetic Foot Ulcerss. The companies which have their Diabetic Foot Ulcerss drug candidates in the most advanced stage, i.e. Phase II include, Charsire Biotechnology Corporation.

• Phases

DelveInsight’s report covers around 34+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Diabetic Foot Ulcerss pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Diabetic Foot Ulcerss: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Diabetic Foot Ulcerss therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Foot Ulcerss drugs.

Diabetic Foot Ulcerss Report Insights

• Diabetic Foot Ulcerss Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Diabetic Foot Ulcerss Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Diabetic Foot Ulcerss drugs?
• How many Diabetic Foot Ulcerss drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic Foot Ulcerss?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Diabetic Foot Ulcerss therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Diabetic Foot Ulcerss and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• NovaLead Pharma
• Helixmith
• ShangHai HaiHe Pharmaceutical
• Beyond Air
• TaiGen Biotechnology
• RHEACELL
• TaiGen Biotechnology
• Technophage
• Transwell Biotech
• Roche
• Chiesi Farmaceutici
• Aurealis Therapeutics
• ZZ Biotech
• APstem Therapeutics
• Charsire Biotechnology Corporation

Key Products

• Galnobax
• VM-202
• CSTC1
• APZ2
• Nemonoxacin
• TP-102
• TWB-103
• Efmarodocokin alfa
• AUP 16
• Cymerus MSC
• 3K3A-APC